JP7088473B2 - ペルオキシソーム障害および白質ジストロフィーの処置のための組成物および方法 - Google Patents

ペルオキシソーム障害および白質ジストロフィーの処置のための組成物および方法 Download PDF

Info

Publication number
JP7088473B2
JP7088473B2 JP2018521617A JP2018521617A JP7088473B2 JP 7088473 B2 JP7088473 B2 JP 7088473B2 JP 2018521617 A JP2018521617 A JP 2018521617A JP 2018521617 A JP2018521617 A JP 2018521617A JP 7088473 B2 JP7088473 B2 JP 7088473B2
Authority
JP
Japan
Prior art keywords
leukodystrophy
dendrimer
peroxisome
disease
cerebral
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018521617A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018531965A5 (enExample
JP2018531965A (ja
Inventor
スハタ カナン，
カナン ランガラマヌジャム，
ファン ザン，
セイエド アリ ファテミ，
ベラ ターク，
オズグル ゴック，
Original Assignee
ザ・ジョンズ・ホプキンス・ユニバーシティー
ケネディー クリーガー インスティテュート， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ザ・ジョンズ・ホプキンス・ユニバーシティー, ケネディー クリーガー インスティテュート， インコーポレイテッド filed Critical ザ・ジョンズ・ホプキンス・ユニバーシティー
Publication of JP2018531965A publication Critical patent/JP2018531965A/ja
Publication of JP2018531965A5 publication Critical patent/JP2018531965A5/ja
Priority to JP2022087580A priority Critical patent/JP2022105767A/ja
Application granted granted Critical
Publication of JP7088473B2 publication Critical patent/JP7088473B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/595—Polyamides, e.g. nylon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0032—Methine dyes, e.g. cyanine dyes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0054—Macromolecular compounds, i.e. oligomers, polymers, dendrimers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/18—Antioxidants, e.g. antiradicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Reproductive Health (AREA)
  • Rheumatology (AREA)
  • Pathology (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pregnancy & Childbirth (AREA)
  • Dermatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
JP2018521617A 2015-10-29 2016-10-31 ペルオキシソーム障害および白質ジストロフィーの処置のための組成物および方法 Active JP7088473B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022087580A JP2022105767A (ja) 2015-10-29 2022-05-30 ペルオキシソーム障害および白質ジストロフィーの処置のための組成物および方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562248163P 2015-10-29 2015-10-29
US62/248,163 2015-10-29
PCT/US2016/059697 WO2017075580A1 (en) 2015-10-29 2016-10-31 Compositions and methods for treatment of peroxisomal disorders and leukodystrophies

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022087580A Division JP2022105767A (ja) 2015-10-29 2022-05-30 ペルオキシソーム障害および白質ジストロフィーの処置のための組成物および方法

Publications (3)

Publication Number Publication Date
JP2018531965A JP2018531965A (ja) 2018-11-01
JP2018531965A5 JP2018531965A5 (enExample) 2019-12-12
JP7088473B2 true JP7088473B2 (ja) 2022-06-21

Family

ID=57233968

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018521617A Active JP7088473B2 (ja) 2015-10-29 2016-10-31 ペルオキシソーム障害および白質ジストロフィーの処置のための組成物および方法
JP2022087580A Pending JP2022105767A (ja) 2015-10-29 2022-05-30 ペルオキシソーム障害および白質ジストロフィーの処置のための組成物および方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022087580A Pending JP2022105767A (ja) 2015-10-29 2022-05-30 ペルオキシソーム障害および白質ジストロフィーの処置のための組成物および方法

Country Status (7)

Country Link
US (2) US20170119899A1 (enExample)
EP (1) EP3368088B1 (enExample)
JP (2) JP7088473B2 (enExample)
CN (1) CN108430514B (enExample)
AU (1) AU2016343855B2 (enExample)
CA (1) CA3003589C (enExample)
WO (1) WO2017075580A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6342575B2 (ja) * 2014-08-13 2018-06-13 ザ・ジョンズ・ホプキンス・ユニバーシティー 脳腫瘍への選択的デンドリマー送達
EP3615086A4 (en) 2017-04-27 2021-01-06 The Johns Hopkins University COMPOSITIONS OF DENDRIMERS FOR USE IN ANGIOGRAPHY
WO2018208707A1 (en) * 2017-05-08 2018-11-15 Neurovia, Inc. Methods and compositions for treating demyelinating diseases
CN111615528A (zh) 2017-11-10 2020-09-01 约翰霍普金斯大学 树枝状聚合物递送系统和其使用方法
US11679104B2 (en) 2017-12-15 2023-06-20 Duke University Compositions and methods of enhancing the homing and/or engraftment of hematopoietic cells in the central nervous system
EP3866811A4 (en) * 2018-10-19 2022-11-02 Disarm Therapeutics, Inc. INHIBITORS OF SARM1 IN COMBINATION WITH NAD+ OR A NAD+ PRECURSOR
WO2020142373A1 (en) * 2019-01-02 2020-07-09 Mayo Foundation For Medical Education And Research Methods and materials for treating leukodystrophies
JP7759322B2 (ja) 2019-12-04 2025-10-23 アシュバッタ セラピューティクス， インコーポレイテッド 眼に薬物送達するためのデンドリマー組成物および方法
CN116075322A (zh) * 2020-04-24 2023-05-05 阿什瓦塔治疗股份有限公司 用于治疗重度急性呼吸窘迫综合征的树枝状大分子组合物和方法
PH12023550133A1 (en) * 2020-07-17 2024-06-24 Ashvattha Therapeutics Inc Dendrimer compositions and methods for drug delivery to injured kidney
WO2023081750A1 (en) * 2021-11-04 2023-05-11 The Children's Hospital Of Philadelphia Compositions and methods for treating metachromatic leukodystrophy disease and related disorders
WO2024081687A2 (en) * 2022-10-12 2024-04-18 The Johns Hopkins University Method of treating lbsl by enhancing dars2 expression
CN116082153A (zh) * 2022-12-09 2023-05-09 长沙贝塔医药科技有限公司 一种丙烯酸酯类衍生物-13c的制备方法
EP4410284A1 (en) * 2023-02-02 2024-08-07 Apteeus Compound and method for the treatment of zellweger spectrum disorder
CN117643581A (zh) * 2023-11-29 2024-03-05 徐州医科大学 白藜芦醇在制备激活sirt1基因的药物中的应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010540664A (ja) 2007-10-05 2010-12-24 ウェイン ステート ユニバーシティー 合成物の持続的な放出のためのデンドリマー
US20120003155A1 (en) 2009-06-15 2012-01-05 National Institutes Of Health Dendrimer based nanodevices for therapeutic and imaging purposes
WO2015027068A1 (en) 2013-08-21 2015-02-26 Concordia University Dendrimer-resveratrol complex

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2212047C (en) 1995-02-07 2010-11-16 Saul W. Brusilow Triglycerides and ethyl esters of phenylalkanoic acid and phenylalkenoic acid useful in treatment of various disorders
CA2344717A1 (en) * 1998-09-28 2000-04-06 The Johns Hopkins University Adrenoleukodystrophy treatments and drug screening
US8148356B2 (en) 2005-08-24 2012-04-03 Cumberland Pharmaceuticals, Inc. Acetylcysteine composition and uses therefor
TW200817369A (en) * 2006-05-22 2008-04-16 Elan Pharm Inc Preparation of polymer conjugates of therapeutic, agricultural and food additive compounds
US8642012B2 (en) 2008-04-29 2014-02-04 Hyperion Therapeutics, Inc. Methods of treatment using ammonia-scavenging drugs
WO2009142754A1 (en) * 2008-05-22 2009-11-26 Goverment Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Dendritic conjugates and methods of use
WO2012012640A1 (en) 2010-07-21 2012-01-26 Cumberland Pharmaceuticals, Inc. Acetycysteine compositions and methods of use thereof
BR112014007357B1 (pt) 2011-09-30 2022-12-06 Immedica Pharma Ab Método para determinar o ajuste da dosagem de um fármaco de varredura de nitrogênio
JP2016517883A (ja) * 2013-05-03 2016-06-20 オレゴン ヘルス アンド サイエンス ユニバーシティー Ｘ連鎖副腎白質ジストロフィーの処置におけるソベチロムの使用
US20160122406A1 (en) * 2013-06-07 2016-05-05 The Administrators Of The Tulane Educational Fund Analogs of pituitary adenylate cyclase-activating polypeptide (pacap) and methods for their use
US20170232120A1 (en) * 2014-08-13 2017-08-17 The Johns Hopkins University Dendrimer compositions and use in treatment of neurological and cns disorders

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010540664A (ja) 2007-10-05 2010-12-24 ウェイン ステート ユニバーシティー 合成物の持続的な放出のためのデンドリマー
US20120003155A1 (en) 2009-06-15 2012-01-05 National Institutes Of Health Dendrimer based nanodevices for therapeutic and imaging purposes
WO2015027068A1 (en) 2013-08-21 2015-02-26 Concordia University Dendrimer-resveratrol complex

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
ACS Nano，2014年02月05日，Vol. 8, No. 3，pp. 2134-2147
Brain Pathology，2010年，Vol. 20，pp. 845-856
Journal of Controlled Release，2015年，Vol. 214，pp. 112-120
Journal of Neuropathology and Experimental Neurology，2000年，Vol. 59, No. 2，pp. 89-102
Nature Medicine，1998年，Vol. 4, No. 11，pp. 1261-1268
The Journal of Cell Biology，2005年，Vol. 169, No. 1，pp.93-104
メルクマニュアル 第１８版 日本語版，初版第３刷，2007年，pp. 2626-2627，（最終査読2016年１月のMSDマニュアルプロフェッショナル版のウェブページも添付した。）

Also Published As

Publication number Publication date
CA3003589A1 (en) 2017-05-04
AU2016343855B2 (en) 2019-10-03
US20220071923A1 (en) 2022-03-10
WO2017075580A1 (en) 2017-05-04
EP3368088C0 (en) 2023-06-07
CA3003589C (en) 2021-12-07
AU2016343855A1 (en) 2018-05-10
JP2022105767A (ja) 2022-07-14
US20170119899A1 (en) 2017-05-04
JP2018531965A (ja) 2018-11-01
CN108430514B (zh) 2023-11-03
EP3368088B1 (en) 2023-06-07
EP3368088A1 (en) 2018-09-05
CN108430514A (zh) 2018-08-21

Similar Documents

Publication Publication Date Title
JP7088473B2 (ja) ペルオキシソーム障害および白質ジストロフィーの処置のための組成物および方法
US20250205369A1 (en) Dendrimer compositions and use in treatment of neurological and cns disorders
Zhou et al. Modified ZIF-8 nanoparticles attenuate osteoarthritis by reprogramming the metabolic pathway of synovial macrophages
He et al. Intelligent lesion blood–brain barrier targeting nano-missiles for Alzheimer's disease treatment by anti-neuroinflammation and neuroprotection
US20210252153A1 (en) Selective dendrimer delivery to brain tumors
Hsu et al. Enhanced delivery of α-glucosidase for Pompe disease by ICAM-1-targeted nanocarriers: comparative performance of a strategy for three distinct lysosomal storage disorders
Haroon et al. Engineered exosomes mediated targeted delivery of neuroprotective peptide NR2B9c for the treatment of traumatic brain injury
Cheong et al. Superparamagnetic iron oxide nanoparticles-loaded chitosan-linoleic acid nanoparticles as an effective hepatocyte-targeted gene delivery system
US20220080056A1 (en) Dendrimer compositions and use in treatment of necrotizing enterocolitis and other gastrointestinal disorders
Zhou et al. ROS/Electro dual-reactive nanogel for targeting epileptic foci to remodel aberrant circuits and inflammatory microenvironment
Kanthi et al. Nanotherapeutic shots through the heart of plaque
CA3189682A1 (en) Dendrimer compositions and methods for drug delivery to injured kidney
CN119053344A (zh) 用于靶向递送治疗剂至神经元的树枝状聚合物组合物
Lim et al. Intracellular uptake mechanism of bioorthogonally conjugated nanoparticles on metabolically engineered mesenchymal stem cells
Modi et al. Dendrimers in the management of Alzheimer's disease
Wang et al. Mitochondria-targeting Cu2-xSe-TPP with dual enzyme activity alleviates Alzheimer's disease by modulating oxidative stress
Li et al. Construction of hyaluronic acid-functionalized magnolol nanoparticles for ulcerative colitis treatment
Machtoub et al. Amyotrophic lateral sclerosis: Advances and perspectives of neuronanomedicine
Rani et al. Nanotherapeutics and Rheumatoid Arthritis: Different Types of Nanomedicines Used in Arthritis
Dar et al. Neuron‐targeted 2‐deoxyglucose‐dendrimer‐rosiglitazone nanotherapy mitigates neuroinflammation and cognitive deficits in pediatric traumatic brain injury
US20250352653A1 (en) Neuron targeted 2-deoxyglucose dendrimer for imaging and treatment of neurological diseases
Wilkinson Engineering Dendrimers for Drug Delivery in CNS Applications
CN118022007A (zh) 一种可降解的功能化FeNi磷酸盐纳米探针、其制备方法及其应用
Winter Identification and Characterization of Carrier Transport Systems Influencing Agmatine Disposition

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191030

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20191030

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20201002

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210104

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210524

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210823

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211022

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220331

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220502

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220530

R150 Certificate of patent or registration of utility model

Ref document number: 7088473

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250